Oxbryta® Product Registry Study is a research project to see how a medicine called Oxbryta works for people with sickle cell disease (SCD). SCD is a condition where red blood cells, which carry oxygen, are shaped like a sickle and can block blood flow.
The study takes place at about 45 places in the United States. It is observational, meaning it just watches and collects information, without giving any specific treatments. People who are already on Oxbryta or about to start it might join. They will continue their normal treatment with their own doctor, and the study will use their medical records to gather data. Participants might stay in the study for up to 5 years, but they can stop anytime. There are no set rules for how they should take Oxbryta; their doctor decides.
- Length of study: Up to 5 years.
- Visits: Regular data collection from medical records, not extra clinic visits.
- Eligibility: Must be on Oxbryta and have SCD; cannot join if in another trial.